Skip to content
Bored Studies
Recruiting

Sola2 AMF Knee System Added to Surgery and Antibiotics in Adults With Knee Implant Infection

Solenic Medical, Inc. · NCT07700927

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 22+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Not applicable
Target enrollment
165
US sites recruiting
2
Study start
October 30, 2026
Record last updated
October 30, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to learn whether the Sola2 AMF Knee System, when added to surgery and antibiotic treatment, can safely improve outcomes, knee function, and quality of life in adults with knee implant infection.

The main questions this study aims to answer are:

  • Whether adding the Sola2 AMF Knee System improves knee function and quality of life at 6 months.
  • Whether adding the Sola2 AMF Knee System to surgery and antibiotic treatment affects the need for additional infection-related surgery.
  • Whether the Sola2 AMF Knee System can be used safely, based on device-related adverse events through 12 months.

This study has two stages. In Stage 1, participants will be enrolled into sequential sentinel groups at increasing AMF temperature levels. All sentinel participants will receive active Sola2 AMF treatment. A safety review will occur after each sentinel group before proceeding to the next group. In Stage 2, researchers will compare participants who receive active Sola2 AMF treatment to participants who receive sham AMF treatment. All participants will receive surgery called debridement, antibiotics, and implant retention (DAIR), and antibiotic treatment for knee implant infection.

Participants will

  • Have DAIR surgery for knee implant infection;
  • Receive pathogen-appropriate antibiotic treatment from the study doctor;
  • If enrolled in Stage 1, receive active Sola2 AMF treatment at the designated sentinel temperature level;
  • If enrolled in Stage 2, receive either active Sola2 AMF treatment or sham AMF treatment, depending on randomization assignment; and
  • Complete follow-up visits and assessments for safety, infection status, pain, knee function, x-rays, laboratory tests, and other study-related outcomes.

Being studied: Intervention 1: Alternating Magnetic Field Treatment; Intervention 2 - Sham Treatment; Debridement, Antibiotics, Implant Retention

Conditions: Prosthetic Joint Infection of Knee

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

Eligible participants must meet all of the following criteria:

  • Adult male or female participant aged ≥ 22 years at the time of surgery.
  • PJI diagnosis of "infected" knee per the 2018 MSIS Definition of Periprosthetic Hip and Knee Infection.
  • Patient presents with PJI symptoms lasting for ≤ 45 days.
  • Well-fixed and functioning prosthesis during clinical exam at screening.
  • Patient to be treated with DAIR, polyethylene spacer exchange and pathogen- appropriate antibiotic therapy.
  • Implanted knee prosthesis must appear on the "AMPLIFY Implant List".
  • All implanted knee prosthesis components must have a legible device identification label (implant sticker) available in the medical record.
  • Able to comprehend and comply with postoperative instructions and willing to return for follow-up visits for the duration of the study.
  • Consent to participate in study and sign the Informed Consent Form (ICF).

Exclusion Criteria

Participants meeting any of the following criteria will be excluded:

  • Implanted knee prosthesis not appearing on the "AMPLIFY Implant List".
  • Implanted knee prosthesis has any femoral and/or tibial augments, sleeves, cones, or modified/extended stems.
  • Un-resurfaced patella.
  • Metal-backed patellar components.
  • Patients not indicated for a DAIR procedure pre-operatively.
  • Patients undergoing bilateral DAIR procedures during the same surgical session.
  • Pre-operative determination that the surgical wound cannot be closed primarily and requires a wound vac as a method of wound closure (e.g., open wound managed for secondary intention healing or delayed primary closure); Use of closed-incision negative pressure therapy over a primarily closed incision is permitted.
  • Previous DAIR procedure(s) performed on the affected knee joint within the last two years.
  • Patients presenting with PJI symptoms lasting for >45 days.
  • Patients on antibiotic therapy for an infection other than PJI of the knee.
  • Body Mass Index (BMI) ≥ 45.
  • Patients currently on bone-marrow suppressive chemotherapy for malignancy.
  • Patients currently with active neutropenia.
  • Presence of metallic implant(s), other than the femoral and tibial components, within the Sola2 treatment zone (+/- 20 centimeters from the knee joint line) including intramedullary nails, hip prosthesis femoral stem, or fracture fixation hardware.
  • Patients with an upper-thigh circumference greater than 70 centimeters (cm) (28 inches (in), measured approximately 15 cm (6 in) proximal to the superior pole of the patella.
  • Patients with implanted or nonremovable cardiac pacemakers, defibrillators or cardioverters, insulin pumps, nerve stimulators, or any other indwelling infusion pump.
  • Patients who are pregnant or nursing.

Recruiting US locations

  • Mount Carmel New Albany Surgical Hospital (JIS Orthopedics)

    New Albany, OH 43054

    Site contact: Michael Sneller, Clinical Research Coordinator · 614-964-0348 · SnellerMA@jisortho.com

  • Oklahoma Surgical Hospital

    Tulsa, OK 74137

    Site contact: Sandy Black, RN CCRC · 918-494-2665 · sblack@oksurg.com

Study contacts (from the official record)

  • Vice President Clinical Operations · U.S.: 877-765-2612 · denise.stamos@solenic.com
  • Chief Medical Officer · U.S.: 877-765-3612 · david.greenberg@solenic.com